PALO ALTO, Calif.--Incyte Pharmaceuticals has completed its acquisition of the gene expression microarray company Synteni that was announced in December. The transaction involves Incyte's issuing shares of its common stock in exchange for all of Synteni's outstanding equity.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.